<DOC>
	<DOCNO>NCT02625974</DOCNO>
	<brief_summary>This study design develop well understand efficacy , safety/tolerability , pharmacokinetics ( PK ) ( absorption , distribution , metabolism , elimination ) nifurtimox child diagnosis Chagas ' disease ( Trypanosoma cruzi infection ) use pediatric formulation .</brief_summary>
	<brief_title>Prospective Study Pediatric Nifurtimox Formulation Chagas ' Disease</brief_title>
	<detailed_description />
	<mesh_term>Chagas Disease</mesh_term>
	<mesh_term>Nifurtimox</mesh_term>
	<criteria>Male female pediatric subject age 0 day young 18 year Chagas ' disease diagnosed/confirmed : Subjects &lt; 8 month age randomization must demonstrate direct observation Trypanosoma cruzi concentration test Subjects â‰¥ 8 month &lt; 18 year age randomization must demonstrate positive conventional ELISA result follow test confirm diagnosis : Recombinant ELISA Total purify antigen ELISA Females childbearing potential ( i.e. , female subject experience menarche ) male subject must agree use adequate contraception sexually active time signing informed consent/assent form 3 month last study drug administration . Subjects age 0 27 day , birth , preterm ( i.e. , gestational age le 37 week ) , weigh less 2500 g , maximum Apgar score &lt; 7 5 minute Subjects follow condition associate Chagas ' disease , : Known evidence Chagas ' diseaserelated cardiomyopathy/Chagas ' heart disease Known evidence Chagas ' diseaserelated gastrointestinal dysfunction ( e.g. , megaoesophagus , megacolon , ) Chagas ' digestive disease Clinically significant psychiatric disorder ( e.g. , moderate severe depression , severe anxiety , psychosis ) epilepsy Subjects contraindications/warnings nifurtimox administration , condition may increase risk undesirable effect nifurtimox , include : Hypersensitivity nifurtimox hydantoin , excipients Suspected known porphyria Severe renal impairment Severe hepatic impairment History brain injury , predisposition seizure epilepsy , psychiatric disease , serious behavioral alteration Subjects previous treatment trypanocidal agent accept indication antiparasitic therapy ( e.g. , reactivation Chagas ' infection due immunosuppression several disease treatment steroid ) Subjects live housing condition active effective vector control T. cruzi reinfection determine Ministry Health guideline country</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>